Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies

Dalakas MC (Guest editor). Therapy in autoimmune neurological diseases neurotherapeutics 2016; Issue 13. The Journal of the American Society for Experimental NeuroTherapeutics, Inc. Springer Publisher; 2016 Dalakas MC. Neuro-immunotherapies: a 30-year retrospective of an overwhelming success and a brighter future. Neurotherapeutics. 2016;13(1):1–3. Dalakas MC, Wiendl H (Guest editors). Antibody therapies in neurology neurotherapeutics 2022. The Journal of the American Society for Experimental NeuroTherapeutics, Inc. Springer Publisher; 2022 (In press) Dalakas MC (Guest editor). Immunotherapy of neurologic diseases. Seminars in Neurology, Vol. 14. Thieme Medical Publishers Inc., New York; 1994. Dalakas MC (Guest editor). Neuroimmunotherapy. Seminars in Neurology, Vol. 23 Thieme Medical Publishers Inc., New York; 2003. Stathopoulos P, Dalakas MC. Evolution of anti‑B cell therapeutics in autoimmune neurological diseases. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01196-w McCombe JA, Pittock SJ. Anti-complement agents for autoimmune neurological disease. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01223-w Nelke C, Spatola M, Schroeter CB, Wiendl H, Lünemann JD. Neonatal Fc receptor–targeted therapies in neurology. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-021-01175-7 Dalakas MC. Autoimmune neurological disorders with IgG4 antibodies: a distinct disease spectrum with unique IgG4 functions responding to anti‑B cell therapies. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01210-1 Krajnc N, Bsteh G, Berger T, Mares J, Hartung H-P. Monoclonal antibodies in the treatment of relapsing multiple sclerosis: an overview with emphasis on pregnancy, vaccination, and risk management. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01224-9 Havla J, Hohlfeld R. Antibody therapies for progressive multiple sclerosis and for promoting repair. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01214-x Krämer J, Wiendl H. What have failed, interrupted, and withdrawn antibody therapies in multiple sclerosis taught us? Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01246-3 Redenbaugh V, Flanagan EP. Monoclonal antibody therapies beyond complement for NMOSD and MOGAD. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01206-x Smets I, Titulaer MJ. Antibody therapies in autoimmune encephalitis. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-021-01178-4 Dalakas MC. Stiff‑person syndrome and GAD antibody‑spectrum disorders: GABAergic neuronal excitability, immunopathogenesis and update on antibody therapies. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01188-w Duong SL, Prüss H. Paraneoplastic autoimmune neurological syndromes and the role of immune checkpoint inhibitors. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01184-0 Querol LA, et al. The role of the complement system in chronic inflammatory demyelinating polyneuropathy—implications for complement-targeted therapies. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01221-y Briani C, Visentin A. Therapeutic monoclonal antibody therapies in chronic autoimmune demyelinating neuropathies. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01222-x Rajabally YA. Antibody therapies in Guillain-Barre syndrome. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01253-4 Vanoli F, Mantegazza R. Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01181-3 Zeng R, Glaubitz S, Schmidt J. Antibody therapies in autoimmune inflammatory myopathies: promising treatment options. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01220-z Cohen F, Yuan H, DePoy EMG, Silberstein SD. The arrival of anti‑CGRP monoclonal antibodies in migraine. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01230-x